In Section C, individuals will acquire ABBV-744 and oral navitoclax. In Phase D, individuals will receive ABBV-744 and ruxolitinib. Contributors will acquire treatment until finally disease progression or perhaps the participants are not able to tolerate the study drugs. Attainable new approaches to the analysis and treatment of AML. (A) https://abbv-744-in-the-treatment46801.blogsumer.com/31323293/the-best-side-of-abbv-744-clinical-trial-phase-1-results